Orum Therapeutics Inc (XKRX:475830) Share Price

Company Profile

Business description
Orum Therapeutics Inc is a biotechnology company that develops anticancer drugs with the technology to attach novel drug payloads to ADC. It can develop all three components of ADC, which consist of antibodies, payloads, and linkers, in-house. The group pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, thereby improving the therapeutic window of drugs. Its services include the modeling, research, development, and testing of pharmaceuticals and treatments for such diseases for Orum’s partners and licensees. The pipeline products are TPD2GSPT1, TPD2PROTAb, and TPS2Cbl-b.
Contact
Munji-ro
281-25, 2nd floor
Yuseong-gu
Munji-dong
Daejeon
KOR
T: +82 427163030
https://www.orumrx.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.

Eric Compton, CFA | 29 October 2026

We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.

Malik Ahmed Khan, CFA | 29 October 2026

Solid results included strong full-self driving software uptake and positive free cash flow.

Seth Goldstein, CFA | 29 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,012.60	41.20	0.46%
CAC 40	7,970.00	83.04	1.05%
DAX 40	26,039.68	335.66	1.31%
Dow JONES (US)	52,342.56	132.54	-0.25%
FTSE 100	10,722.07	27.57	0.26%
HKSE	22,958.65	136.18	-0.59%
NASDAQ	26,184.72	365.13	-1.38%
Nikkei 225	64,659.47	705.28	1.10%
NZX 50 Index	13,736.85	26.68	0.19%
S&P 500	7,720.39	23.59	-0.30%
S&P/ASX 200	8,891.80	44.50	0.50%
SSE Composite Index	3,651.43	30.04	-0.82%